Guggenheim has revised its price target for Biogen (BIIB, Financial), reducing it slightly from $168 to $165 while maintaining a Buy rating on the stock. This adjustment reflects the firm's analysis in anticipation of Biogen's upcoming first-quarter earnings report, which includes evaluating recent developments, company statements, and prescription trends.
The updated price target is part of Guggenheim's broader review of 36 commercial-stage biotechnology companies under its coverage. These revisions are aimed at aligning expectations with current market conditions and ensuring investment strategies are well-informed by the latest available information.
